NEW YORK (GenomeWeb News) – Sequenom said Friday evening that it has received notification from the US Patent and Trademark Office that a patent that was scheduled to issue next week has been withdrawn.

The USPTO said that it has withdrawn the issuance of US Patent No. 8,340,916 due to an anticipated patent interference proceeding between parties with pending patent applications or issued patents covering similar subject matter. Sequenom said that it had previously been notified by the USPTO that the patent would issue on Dec. 25.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Sep
27
Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sep
28
Sponsored by
Fabric Genomics

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.